Simon Quick Advisors LLC Acquires Shares of 857 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Simon Quick Advisors LLC acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 857 shares of the company's stock, valued at approximately $360,000.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth $412,258,000. GAMMA Investing LLC lifted its stake in IDEXX Laboratories by 59,810.7% in the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after purchasing an additional 916,898 shares in the last quarter. Flossbach Von Storch SE grew its position in shares of IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock valued at $195,696,000 after purchasing an additional 464,791 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth about $156,412,000. Finally, William Blair Investment Management LLC lifted its position in shares of IDEXX Laboratories by 701.6% in the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after buying an additional 369,471 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director now owns 1,801 shares of the company's stock, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Trading Up 0.7%

IDEXX Laboratories stock traded up $3.79 during mid-day trading on Monday, hitting $526.49. The company's stock had a trading volume of 63,445 shares, compared to its average volume of 648,298. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a 50 day moving average of $473.11 and a 200-day moving average of $444.61. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $530.73. The stock has a market cap of $42.34 billion, a PE ratio of 49.34, a P/E/G ratio of 3.41 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.71 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on IDXX. Leerink Partners upped their price objective on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a report on Wednesday, June 11th. Stifel Nicolaus lifted their price objective on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday, May 19th. Morgan Stanley lifted their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Finally, Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $546.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.